ArticleDermatology and therapy2026
Patient Experience and Preferences for Treatments in Atopic Dermatitis.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough type 2 inflammatory pathway dysfunction is a hallmark of atopic dermatitis (AD), disease symptoms in many patients are also driven by other immune/inflammatory pathway dysfunctions, all of which lead to varied treatment response profiles of targeted systemic therapies for individual patients. Adding complexity to the process of identifying which systemic therapy to prescribe for an individual patient is that these treatments have varied safety profiles, routes of administration, monitoring requirements, and costs-all of which are reviewed during today's shared decision-making discussions.
methodsThis patient assessment study aimed to better understand patients' attitudes toward contemporary AD treatments, their experiences, and their perceptions of a molecular test to predict treatment response. A 32-question assessment tool, deemed eligible for IRB exemption, was made available to any attendees with AD at the 2024 Eczema Expo who wished to complete it.
resultsRegarding treatment objectives, results indicated the top three factors most important to respondents (n = 40) were itch control (70%), skin clearance (58%), and safety/side effects (50%). For respondents switching from their initial topical therapy due to lack of efficacy (n = 37), 38% switched to a systemic drug. Among respondents who had used targeted systemics (n = 22), 18% switched systemics, 4.5% added another systemic, 32% added topicals, and 45% did not modify their initial systemic treatment. The top two reasons for switching systemics or adding a topical treatment to their systemic were insufficient skin clearance and itch control. Of respondents open to taking a new systemic therapy, 94% showed interest in a test that would inform them about which targeted systemic therapy would work best for them.
conclusionThese findings highlight a clinical need for personalized therapeutic guidance in AD to improve patient care and treatment satisfaction.
Indexed as
Identifiers
42709335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.